It is a small molecule that binds to the extracellular domain of PSMA with high affinity and has shown success in studies evaluating the detection of prostate cancer across a range of disease states, including studies where histopathology served as a reference standard [19-22]. Here, FOLH1 is linked to prostate carcinoma.